-
r37980778c78--3c436db8d8c98b2c2434ca2bc1b885f4
BackgroundIt remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung... -
r37980778c78--13c096d1ab7c7e79f945e76e95ba459c
VATS procedures for non-small cell lung cancer performed by type of the number of port. -
r37980778c78--de2810d9ba30fc09f908c645115cbaba
Main characteristics of the patient population and assessment of generalizability. -
Molecular testing and treatment patterns for patients with advanced non-small...
BackgroundThe goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of... -
r37980778c78--7ec636573ca61b3cd55b536f81eaa1fc
Analysis of relationships between vimentin and clinicopathological variables in NSCLC. -
r37980778c78--c364e66c552cfc7356ffa91494948e54
The baseline characteristics in patients based on PD-L1 expression level. -
Demographic and clinical characteristics of patients by receipt of one or mor...
Demographic and clinical characteristics of patients by receipt of one or more molecular testsa (yes/no) in Japan, Korea, Taiwan, and Brazil. -
r37980778c78--feef0bb0f285c67c668df7b8171817d1
Network meta-analyses: PFS, OS, grade 3–5 AE in all-histology NSCLC. -
r37980778c78--ce343bb5c2fe0d63e8978bffee4fa384
Clinical outcomes of pembrolizumab monotherapy according to PD-L1 expression level. -
ADC Histogram Parameters of Pathologic Grades of NSCLC.
ADC Histogram Parameters of Pathologic Grades of NSCLC. -
r37980778c78--fe800cb4e92007f8f9ae6596361ba8b6
Studies evaluating treatment patterns in patients with advanced non-small cell lung cancer by country. -
Overall survival by NSCLC histology, predictive biomarker testing, and mutati...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement).
